- Home
- RDHL
as 04-01-2025 3:41pm EST
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
| Founded: | 2009 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 120.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -38.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.47 - $20.28 | Next Earning Date: | 04-11-2025 |
| Revenue: | $3,707,000 | Revenue Growth: | -89.63% |
| Revenue Growth (this year): | 224.9% | Revenue Growth (next year): | 82.69% |
Latest Redhill Biopharma Ltd. News
RDHL Breaking Stock News: Dive into RDHL Ticker-Specific Updates for Smart Investing
MT Newswires
14 days ago
RedHill Biopharma Plans to File for UK Approval of H.Pylori Treatment
PR Newswire
14 days ago
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
PR Newswire
20 days ago
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results
PR Newswire
a month ago
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
Pharmaceutical Technology
a month ago
RedHill and Hyloris sign agreement for Bekinda’s development
PR Newswire
a month ago
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
Clinical Trials Arena
2 months ago
RedHill Biopharma launches trial of combination therapy for prostate cancer
MT Newswires
2 months ago
RedHill Biopharma Begins Phase 2 Study of Opaganib, Darolutamide for Advanced Prostate Cancer; Shares Rise
Compare RDHL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RDHL Redhill Biopharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.